Interferon agent in the comprehensive treatment of patients with tuberculosis and viral hepatitis c
Mordyk A. V., Ivanova O. G., Semenenko T. A.
Инфекционные болезни
Vol.17, Issue1, P. 180-185
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.20953/1729-9225-2019-1-180-185
Аннотация:
We performed a prospective randomized open-label controlled trial of Viferon in patients with pulmonary tuberculosis (TB) coinfected with viral hepatitis C. Sixty TB patients were recruited into the study and randomized into 2 groups. The experimental group included 30 patients receiving Viferon® (1 suppository (3 000 000 IU) 2 times a day during the first 10 days and then 1 suppository twice a week during the next 6 months). The control group comprised 30 patients that did not receive Viferon®. In the experimental group, we observed an improvement of some immunological parameters, including an increase in phagocytic activity of leukocytes, T-lymphocyte count, and IFN-α level (р = 0.001) and a decrease in the level of stimulated IFN-γ (р = 0.054). By the end of the treatment course, sputum negativation was confirmed in 18 patients (75.0[%]) from the experimental group and 17 patients (68.0[%]) from the control group. Closure of cavities was observed in 6 participants (33.3[%]) receiving Vife
Ключевые слова:
Recombinant human interferon alpha-2b; Tuberculosis; Viferon; Viral hepatitis C
alpha interferon; gamma interferon; interferon; viferon; Article; controlled study; hepatitis C; human; human cell; leukocyte; lung tuberculosis; lymphocyte count; major clinical study; open study; prospective study; randomized controlled trial; suppository; T lymphocyte
Язык текста: Английский
ISSN: 2414-9691
Mordyk A. V.
Ivanova O. G.
Semenenko T. A. Tat`yana Anatolyevna 1949-
Мордyк А. В.
Иванова О. Г.
Семененко Т. А. Татьяна Анатольевна 1949-
Interferon agent in the comprehensive treatment of patients with tuberculosis and viral hepatitis c
Текст визуальный непосредственный
Инфекционные болезни
ООО "Издательство "Династия"
Vol.17, Issue1 P. 180-185
2019
Статья
Recombinant human interferon alpha-2b Tuberculosis Viferon Viral hepatitis C
alpha interferon gamma interferon interferon viferon Article controlled study hepatitis C human human cell leukocyte lung tuberculosis lymphocyte count major clinical study open study prospective study randomized controlled trial suppository T lymphocyte
We performed a prospective randomized open-label controlled trial of Viferon in patients with pulmonary tuberculosis (TB) coinfected with viral hepatitis C. Sixty TB patients were recruited into the study and randomized into 2 groups. The experimental group included 30 patients receiving Viferon® (1 suppository (3 000 000 IU) 2 times a day during the first 10 days and then 1 suppository twice a week during the next 6 months). The control group comprised 30 patients that did not receive Viferon®. In the experimental group, we observed an improvement of some immunological parameters, including an increase in phagocytic activity of leukocytes, T-lymphocyte count, and IFN-α level (р = 0.001) and a decrease in the level of stimulated IFN-γ (р = 0.054). By the end of the treatment course, sputum negativation was confirmed in 18 patients (75.0[%]) from the experimental group and 17 patients (68.0[%]) from the control group. Closure of cavities was observed in 6 participants (33.3[%]) receiving Vife